AmoyDx Overview
- Year Founded
-
2008
- Status
-
Public
- Employees
-
1,144
- Stock Symbol
-
300685
- Investments
-
1
- Share Price
-
$2.83
- (As of Friday Closing)
AmoyDx General Information
Description
Amoy Diagnostics Co Ltd is the pharmaceutical company based in China. The company primarily focuses on molecular diagnostics for oncology precision medicine. It provides diagnostic products and services for medicine development and clinical oncology practice. The company's products include gene mutation, nucleic acid extraction, and molecular diagnostic kits comprising EGFR, RAS, ALK, BRAF, PIK3CA, and ROS1 testing kits.
Contact Information
Website
www.amoydiagnostics.comCorporate Office
- 39 Dingshan Road
- Haicang District
- Xiamen, Fujian 361027
- China
Corporate Office
- 39 Dingshan Road
- Haicang District
- Xiamen, Fujian 361027
- China
AmoyDx Stock Performance
As of 09-May-2025, AmoyDx’s stock price is $2.83. Its current market cap is $1.11B with 393M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.83 | $2.89 | $2.37 - $4.10 | $1.11B | 393M | 8.78M | $0.10 |
AmoyDx Financials Summary
As of 31-Mar-2025, AmoyDx has a trailing 12-month revenue of $159M.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 1,065,198 | 1,097,495 | 1,119,321 | 1,417,182 |
| Revenue | 159,296 | 154,547 | 147,495 | 125,054 |
| EBITDA | 40,482 | 44,668 | 47,128 | 49,482 |
| Net Income | 39,019 | 35,519 | 36,960 | 39,163 |
| Total Assets | 297,849 | 282,846 | 272,957 | 239,289 |
| Total Debt | 7,796 | 7,843 | 7,996 | 7,775 |
AmoyDx Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
AmoyDx Comparisons
Industry
Financing
Details
AmoyDx Competitors (8)
One of AmoyDx’s 8 competitors is Indivumed Therapeutics, a Private Debt Financed company based in Hamburg, Germany.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Indivumed Therapeutics | Private Debt Financed | Hamburg, Germany | ||||
| Biotium | Private Debt Financed | Fremont, CA | ||||
| Biologos | Private Equity-Backed | Glendale Heights, IL | ||||
| InVitria | Corporation | Junction City, KS | ||||
| Teknova | Formerly VC-backed | Hollister, CA |
AmoyDx Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
AmoyDx Patents
AmoyDx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4328920-A1 | Microsatellite instability detection method based on second-generation sequencing | Pending | 20-Apr-2021 | ||
| EP-4328920-A4 | Microsatellite instability detection method based on second-generation sequencing | Pending | 20-Apr-2021 | ||
| US-20230146580-A1 | Constructing method of genomic scar model | Pending | 07-Sep-2020 | ||
| EP-4213152-A1 | Method for establishing genomic scar model | Pending | 07-Sep-2020 | ||
| EP-4213152-A4 | Method for establishing genomic scar model | Pending | 07-Sep-2020 | G16H50/50 |
AmoyDx Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
AmoyDx Investments (1)
AmoyDx’s most recent deal was a Early Stage VC with Universal Sequencing Technology for . The deal was made on 24-May-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Universal Sequencing Technology | 24-May-2018 | Early Stage VC | Biotechnology |
AmoyDx ESG
Risk Overview
Risk Rating
Updated September, 27, 2023
31.83 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,631
Rank
Percentile
Healthcare
Industry
of 563
Rank
Percentile
Medical Devices
Subindustry
of 196
Rank
Percentile
AmoyDx FAQs
-
When was AmoyDx founded?
AmoyDx was founded in 2008.
-
Where is AmoyDx headquartered?
AmoyDx is headquartered in Xiamen, China.
-
What is the size of AmoyDx?
AmoyDx has 1,144 total employees.
-
What industry is AmoyDx in?
AmoyDx’s primary industry is Biotechnology.
-
Is AmoyDx a private or public company?
AmoyDx is a Public company.
-
What is AmoyDx’s stock symbol?
The ticker symbol for AmoyDx is 300685.
-
What is the current stock price of AmoyDx?
As of 09-May-2025 the stock price of AmoyDx is $2.83.
-
What is the current market cap of AmoyDx?
The current market capitalization of AmoyDx is $1.11B.
-
What is AmoyDx’s current revenue?
The trailing twelve month revenue for AmoyDx is $159M.
-
Who are AmoyDx’s competitors?
Indivumed Therapeutics, Biotium, Biologos, InVitria, and Teknova are some of the 8 competitors of AmoyDx.
-
What is AmoyDx’s annual earnings per share (EPS)?
AmoyDx’s EPS for 12 months was $0.10.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
